Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07 Agosto 2024 - 3:30PM
Esperion (NASDAQ: ESPR) today announced that on August 7, 2024, the
Company granted 18 new employees 66,800 restricted stock units
(RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan.
The 2017 Inducement Equity Incentive Plan is used exclusively
for the grant of equity awards to individuals who were not
previously an employee or non-employee director of Esperion (or
following a bona fide period of non-employment), as an inducement
material to such individual's entering into employment with
Esperion, pursuant to Rule 5635(c)(4) of the NASDAQ Listing
Rules.
Each RSU will vest and become exercisable as to 25 percent of
the shares on the one-year anniversary of the recipient’s vesting
commencement date and will vest and become exercisable as to the
remaining 75 percent of the shares in twelve equal quarterly
installments at the end of each quarter following such anniversary,
in each case, subject to each such employee's continued employment
with Esperion on such vesting dates. The RSUs are subject to the
terms and conditions of Esperion’s 2017 Inducement Equity Incentive
Plan, and the terms and conditions of the RSU agreement covering
the grant.
Esperion TherapeuticsAt Esperion, we discover,
develop, and commercialize innovative medicines to help improve
outcomes for patients with or at risk for cardiovascular and
cardiometabolic diseases. The status quo is not meeting the health
needs of millions of people with high cholesterol – that is why our
team of passionate industry leaders is breaking through the
barriers that prevent patients from reaching their goals. Providers
are moving toward reducing LDL-cholesterol levels as low as
possible, as soon as possible; we provide the next steps to help
get patients there. Because when it comes to high cholesterol,
getting to goal is not optional. It is our life’s work. For more
information, visit esperion.com and esperionscience.com and follow
us on Twitter at twitter.com/EsperionInc.
Esperion Contact Information:Investors:Alina
Veneziainvestorrelations@esperion.com(734) 887-3903
Media:Tiffany Aldrichcorporateteam@esperion.com(616)
443-8438
Esperion Therapeutics (NASDAQ:ESPR)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Esperion Therapeutics (NASDAQ:ESPR)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024